2. Academic Validation
  3. Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne

Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne

  • Bioorg Med Chem Lett. 2018 Jun 1;28(10):1736-1741. doi: 10.1016/j.bmcl.2018.04.036.
Etienne Thoreau 1,  Jean-Marie Arlabosse 1,  Claire Bouix-Peter 2,  Sandrine Chambon 1,  Laurent Chantalat 1,  Sébastien Daver 1,  Laurence Dumais 1,  Gwenaëlle Duvert 1,  Angélique Feret 1,  Gilles Ouvry 1,  Jonathan Pascau 1,  Catherine Raffin 1,  Nicolas Rodeville 1,  Catherine Soulet 1,  Samuel Tabet 1,  Sandrine Talano 1,  Thibaud Portal 1
Affiliations

Affiliations

  • 1 Nestlé Skin Health, Les Templiers 2400 Route des Colles, 06410 Biot, France.
  • 2 Nestlé Skin Health, Les Templiers 2400 Route des Colles, 06410 Biot, France. Electronic address: [email protected].
PMID: 29706423 DOI: 10.1016/j.bmcl.2018.04.036
Abstract

Retinoids have a dominant role in topical acne therapy and to date, only RARβ and RARγ dual agonists have reached the market. Given the tissue distribution of RAR isoforms, it was hypothesized that developing RARγ -selective agonists could yield a new generation of topical acne treatments that would increase safety margins while maintaining the robust efficacy of previous drugs. Structural knowledge derived from the X-ray structure of known γ-selective CD437, suggested the design of a novel triaryl series of agonists which was optimized and ultimately led to the discovery of Trifarotene/CD5789.

Keywords

Acne; CD437; CD5789; RARγ; Trifarotene.

Figures
Products